Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar

by | Feb 4, 2026 | Uncategorized

Eli Lilly’s full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments